<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001575</url>
  </required_header>
  <id_info>
    <org_study_id>970110</org_study_id>
    <secondary_id>97-C-0110</secondary_id>
    <nct_id>NCT00001575</nct_id>
    <nct_alias>NCT00019305</nct_alias>
  </id_info>
  <brief_title>Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the use of a radioactive monoclonal antibody called yttrium
      90-labeled humanized anti-Tac (90 Y-HAT) for treating certain cancers. Monoclonal antibodies
      are genetically engineered proteins made in large quantities and directed against a specific
      target in the body. The anti-Tac antibody in this study is targeted to tumor cells and is
      tagged (labeled) with a radioactive substance called Yttrium-90 (Y-90). The study will
      determine the maximum tolerated dose of 90Y-HAT and examine its safety and effectiveness.

      Patients 18 years of age and older with Hodgkin's disease, non-Hodgkin's lymphoma and
      lymphoid leukemia who have proteins on their cancer cells that react with anti-Tac may be
      eligible for this study. Candidates are screened with a medical history and physical
      examination, blood and urine tests, electrocardiogram (EKG), chest x-ray, computed tomography
      (CT) scan or ultrasound of the abdomen, positron emission tomography (PET) scan of the neck
      and body, and skin test for immune reactivity to antigens (similar to skin tuberculin test).

      Before beginning treatment, participants may undergo additional procedures, including the
      following:

        -  Patients with suspicious skin lesions have a skin biopsy. An area of skin is numbed and
           a circular piece of skin about 1/4-inch diameter is removed with a cookie cutter-like
           instrument.

        -  Patients with hearing loss have a hearing test.

        -  Patients with neurological symptoms have a lumbar puncture (spinal tap). A local
           anesthetic is given and a needle is inserted in the space between the bones in the lower
           back where the cerebrospinal fluid circulates below the spinal cord. A small amount of
           fluid is collected through the needle.

        -  Patients who have not had a bone marrow biopsy within 6 months of screening also undergo
           this procedure. The skin and bone at the back of the hip are numbed with a local
           anesthetic and a small piece of bone is withdrawn through a needle.

      Patients receive 90 Y-HAT in escalating doses to determine the highest dose that can be
      safely given. The first group of three patients receives a low dose and, if there are no
      significant side effects at that dose, the next three patients receive a higher dose. This
      continues with subsequent groups until the maximum study dose is reached. 90 Y-HAT is given
      through a vein (intravenous (IV)) over a 2-hour period. In addition, a drug called Pentetate
      Calcium Trisodium Inj (Ca-DTPA) is given via IV over 5 hours for 3 days to help reduce the
      side effects of the 90Y-HAT. In some patients, the 90 Y-HAT may also be attached to a
      radioactive metal called Indium-111 to monitor what happens to the injected material. During
      infusion of the drug, patients undergo PET scanning to trace the path of the injected
      material in the body. For this procedure, the patient lies in the scanner, remaining in one
      position during the entire infusion.

      Blood and urine specimens are collected periodically over a 6-week period following the
      infusion to determine the level of the radioactive antibody. Bone marrow, lymph node, or skin
      biopsies may be done to determine how much of the antibody entered these sites. Patients
      whose disease remains stable or improves with therapy may receive up to six more infusions of
      90 Y-HAT, with at least a 6-week interval between treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Cluster of differentiation 25 (CD25) is expressed on the malignant cells of patients with
      certain lymphoid malignancies as well as the non-malignant T cells that surround the
      malignant tumor cells of patients with Hodgkin's disease.

      Zenapax is a humanized monoclonal antibody that binds to CD25.

      Zenapax has been chemically modified by the addition of a chelating molecule to permit
      binding of radioactive yttrium.

      The yttrium labeled Zenapax binds to CD25 to deliver radiation treatment to the tumor.

      Objective:

      To assess the toxicity and therapeutic efficacy of (90)Yttrium-labeled humanized
      anti-Tac((90)Y-HAT) in patients with Tac-expressing hematologic malignancies.

      To determine the sites of localization of radiolabeled Zenapax.

      Eligibility:

      Patients with Hodgkin's disease and other CD25 positive lymphoid malignancies.

      The patient must have a granulocyte of at least 1,200/mm^3 and a platelet count of greater
      than 100,000/mm^3.

      Design:

      Patients will be treated with 10 mCi (if a bone marrow transplant was part of the patient's
      previous therapy) or 15 mCi of yttrium labeled Zenapax.

      Indium labeled Zenapax is given to demonstrate the antibody distribution and confirm
      localization at sites of tumor.

      Treatment is given every six weeks if tolerated and patients will be hospitalized for about
      one week for each treatment.

      Tumor response will be evaluated after every treatment. Stable or responding patients will
      continue treatment with evaluations after every cycle of treatment. Patients will be treated
      for up to seven cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of 90Y-HAT</measure>
    <time_frame>Patients could receive 90Y-HAT 15mCi per cycle and complete up to a maximum of 7 doses or 2 doses by the average of every 6 weeks.</time_frame>
    <description>Phase I portion maximum tolerated dose (MTD) is defined as the dose level below the dose at which 2 out of 2-6 patients develop DLT (if any patient develops grade IV toxicity of any type (excluding grade IV neutropenia) or grade III non-hematologic toxicity that patient may not continue on the study at the same dose level and therefore has had a dose limiting toxicity). There can be no more than 1 out of 6 patients with DLT at the MTD. The MTD will be assessed using only the results from the first cycle of therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>Patient would be measured with computed tomography (CT) scan, Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scan in 28 days before treatment. Patient would be evaluated with In-HAT imaging at Day 1,4,5,6 and Day 7 in week 1 of each cycle.</time_frame>
    <description>Clinical Response of patient is measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Tumor responses were evaluated by In-HAT imaging (i.e., simultaneous with administration of therapeutic 90Y-daclizumab), Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scans and computed tomography (CT) scans. Complete response is a disappearance of all measurable and evaluable disease lasting more than I month. Partial response is a reduction by ≥ 50% of leukemic cell count or ≥ 50% reduction in the size of all measurable lesions, and no increase in size of any measurable or evaluable lesion or appearance of new lesions for 1 month. Stable disease is less than partial response with no more than a 25% increase in leukemic cell count, no new lesions, or less than a 25% increase in any measurable lesion. Progressive disease is at least a 25% increase in leukemic cell count, appearance of new lesions, or an increase of 25% or greater in any measurable lesion after 2 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>16 yrs 18 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Hodgkin's Disease</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Y-90 Humanized Anti-Tac</intervention_name>
    <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).</description>
    <arm_group_label>Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium-DTPA</intervention_name>
    <description>Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
    <arm_group_label>Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        All patients must have a histologically confirmed diagnosis of Hodgkin's disease. Patients
        who have had an allogeneic or autologous transplant are eligible if they are more than 100
        days post-transplant.

        At least 10% of each patient's malignant cells from peripheral blood, lymph node, skin, or
        other extranodal sites must react with anti-Tac, as determined by immunofluorescent or
        immunoperoxidase staining. Because of the high incidence of Tac positivity in infiltrating
        T cells in Hodgkin's disease, patients with cluster of differentiation 25 (CD25) positive
        infiltrating T cells will be eligible even if the Hodgkin's cells are negative.

        Diagnoses and Stage Disease: 1) Non-Hodgkin's Lymphoma (NHL): Patients with all
        histopathologic subtypes of Tac-expressing NHL are eligible. Patients with indolent NHL
        Stages II through IV are eligible if they have failed at least one standard therapy and
        have disease requiring treatment. Patients with aggressive NHL are eligible if they have
        relapse after standard chemotherapy and either are not eligible for or have refused salvage
        chemotherapy or bone marrow transplantation.

        2) Hodgkin's disease: Patients who are considered to have a low potential for cure with
        conventional chemotherapy or radiation therapy are eligible. Specifically, patients with
        stages II-IV Hodgkin's disease are eligible if they have relapsed or failed to attain a
        complete remission after first-line chemotherapy and either are not eligible for or have
        refused salvage chemotherapy or bone marrow transplantation.

        3) Cutaneous T-cell Lymphoma (CTCL): Patients with all stages of Tac-expressing CTCL are
        eligible with the exception of Stage Ia. Patients with Stages Ib through III are eligible
        if they have failed at least one standard therapy. Patients with stage IV are eligible
        regardless of whether they have had previous therapy.

        4) Peripheral T-cell Lymphoma (PTCL): Patients with stages I - IV PTCL are eligible if they
        have relapsed after first-line chemotherapy and either are not eligible for or have refused
        salvage chemotherapy or bone marrow transplantation.

        Other: Patients with lymphoid leukemias or lymphomas not easily classified in the above
        categories will be eligible providing they have failed standard therapy and are not
        eligible for or have refused bone marrow transplantation.

        Patients must have a Karnofsky performance status of at least 50.

        Patients must have a creatinine of less than 2.0 mg/dl. If they patient has an abnormally
        elevated creatinine a creatinine clearance must be greater than 50 ml/min.

        Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic
        pyruvic transaminase (SGPT) less than 5 times the upper limit of normal, bilirubin less
        than 3.0 unless this is felt to be due to the malignancy.

        Patients must not have clinical cardiac failure. Patients with symptomatic pulmonary
        dysfunction are eligible only if it is due to the underlying malignancy.

        The patient must have a granulocyte count of at least 1,200/mm^3 and a platelet count of
        greater than 100,000/mm^3.

        Patients must be able to understand and sign informed consent.

        Breast-feeding females are not eligible for the study.

        Omission of cytotoxic chemotherapy or other systemic therapy of the malignancy for 3 weeks
        prior to entry into trial. However, patients receiving corticosteroids will not be
        excluded. Patients receiving corticosteroids must be on a stable dose for at least three
        weeks before receiving yttrium 90-labeled humanized anti-Tac (90Y-HAT) on this study.

        Patients must have a life expectancy of greater than 1 month.

        Patients must be at least 18 years old.

        EXCLUSION CRITERIA:

        Female patients of child bearing potential will be tested for pregnancy; pregnant patients
        will be excluded from the study.

        Patients who are human immunodeficiency virus (HIV) antibody positive.

        Patients with symptomatic disease that is due to malignant involvement of the central
        nervous system.

        Patients with active second primary cancer.

        Patients receiving chronic anticoagulant therapy will be excluded from the study.

        Patients requiring urgent chemotherapy or radiation therapy for management of their
        malignancy will be excluded.

        Patients with evidence of myelodysplastic syndrome or chromosomal abnormalities in their
        screening bone marrow evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Waldmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1997-C-0110.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, Top LE, Bamford R, Zaknoen E, Roessler E, Kasten-Sportes C, England R, Litou H, Johnson JA, Jackson-White T, Manns A, Hanchard B, Junghans RP, Nelson DL. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995 Dec 1;86(11):4063-75.</citation>
    <PMID>7492762</PMID>
  </reference>
  <reference>
    <citation>Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991 Aug 15;147(4):1352-9.</citation>
    <PMID>1869828</PMID>
  </reference>
  <reference>
    <citation>Pinkus GS, O'Hara CJ, Said JW. Peripheral/post-thymic T-cell lymphomas: a spectrum of disease. Clinical, pathologic, and immunologic features of 78 cases. Cancer. 1990 Feb 15;65(4):971-98.</citation>
    <PMID>2297666</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <results_first_submitted>May 14, 2015</results_first_submitted>
  <results_first_submitted_qc>October 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2015</results_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Thomas Waldmann, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Yttrium 90</keyword>
  <keyword>Radiolabeled</keyword>
  <keyword>Anti -Tac</keyword>
  <keyword>Calcium DTPA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All ph I pts who received an initial bone marrow transplantation received an initial dose of 10mCi followed by 15mCi. At the discretion of the PI on the basis of persistent reduced hematopoietic values, a subsequent dose may have been reduced from 15mCi to 10mCi or 5mCi. All ph II pts received at least one dose of 10mCi and/or 15mCi, or 20mCi.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)</title>
          <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screening failures-Ph I portion</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn/deaths</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)</title>
          <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of 90Y-HAT</title>
        <description>Phase I portion maximum tolerated dose (MTD) is defined as the dose level below the dose at which 2 out of 2-6 patients develop DLT (if any patient develops grade IV toxicity of any type (excluding grade IV neutropenia) or grade III non-hematologic toxicity that patient may not continue on the study at the same dose level and therefore has had a dose limiting toxicity). There can be no more than 1 out of 6 patients with DLT at the MTD. The MTD will be assessed using only the results from the first cycle of therapy.</description>
        <time_frame>Patients could receive 90Y-HAT 15mCi per cycle and complete up to a maximum of 7 doses or 2 doses by the average of every 6 weeks.</time_frame>
        <population>Phase I portion-maximum tolerated dose. Only the Hodgkin's participants was analyzed (i.e., 28).</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)</title>
            <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of 90Y-HAT</title>
          <description>Phase I portion maximum tolerated dose (MTD) is defined as the dose level below the dose at which 2 out of 2-6 patients develop DLT (if any patient develops grade IV toxicity of any type (excluding grade IV neutropenia) or grade III non-hematologic toxicity that patient may not continue on the study at the same dose level and therefore has had a dose limiting toxicity). There can be no more than 1 out of 6 patients with DLT at the MTD. The MTD will be assessed using only the results from the first cycle of therapy.</description>
          <population>Phase I portion-maximum tolerated dose. Only the Hodgkin's participants was analyzed (i.e., 28).</population>
          <units>mci</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response</title>
        <description>Clinical Response of patient is measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Tumor responses were evaluated by In-HAT imaging (i.e., simultaneous with administration of therapeutic 90Y-daclizumab), Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scans and computed tomography (CT) scans. Complete response is a disappearance of all measurable and evaluable disease lasting more than I month. Partial response is a reduction by ≥ 50% of leukemic cell count or ≥ 50% reduction in the size of all measurable lesions, and no increase in size of any measurable or evaluable lesion or appearance of new lesions for 1 month. Stable disease is less than partial response with no more than a 25% increase in leukemic cell count, no new lesions, or less than a 25% increase in any measurable lesion. Progressive disease is at least a 25% increase in leukemic cell count, appearance of new lesions, or an increase of 25% or greater in any measurable lesion after 2 weeks.</description>
        <time_frame>Patient would be measured with computed tomography (CT) scan, Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scan in 28 days before treatment. Patient would be evaluated with In-HAT imaging at Day 1,4,5,6 and Day 7 in week 1 of each cycle.</time_frame>
        <population>Phase II portion. Only the Hodgkin's participants was analyzed (i.e., added more Hodgkins participants to study).</population>
        <group_list>
          <group group_id="O1">
            <title>Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)</title>
            <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response</title>
          <description>Clinical Response of patient is measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Tumor responses were evaluated by In-HAT imaging (i.e., simultaneous with administration of therapeutic 90Y-daclizumab), Fludeoxyglucose (18F) positron-emission tomography (FDG PET) scans and computed tomography (CT) scans. Complete response is a disappearance of all measurable and evaluable disease lasting more than I month. Partial response is a reduction by ≥ 50% of leukemic cell count or ≥ 50% reduction in the size of all measurable lesions, and no increase in size of any measurable or evaluable lesion or appearance of new lesions for 1 month. Stable disease is less than partial response with no more than a 25% increase in leukemic cell count, no new lesions, or less than a 25% increase in any measurable lesion. Progressive disease is at least a 25% increase in leukemic cell count, appearance of new lesions, or an increase of 25% or greater in any measurable lesion after 2 weeks.</description>
          <population>Phase II portion. Only the Hodgkin's participants was analyzed (i.e., added more Hodgkins participants to study).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>16 yrs 18 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)</title>
            <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Anti-Tac Yttrium 90-labeled Humanized Anti-Tac (90 Y-HAT)</title>
          <description>10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Bone marrow cellularity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN:: Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, tooth pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC:: Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy-Other (Specify,____) excludes metastasis from initial primary</sub_title>
                <description>MDS</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Secondary Malignancy-Other (Specify,____) excludes metastasis from initial primary</sub_title>
                <description>MDS/AML</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Secondary Malignancy-Other (Specify,____) excludes metastasis from initial primary</sub_title>
                <description>myelodysplastic syndrome</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>SYNDROMES:: Syndromes-Other (Specify, MDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY:: Pulmonary-Other (Specify, respiratory failure)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Hemoglobin</sub_title>
                <counts group_id="E1" events="109" subjects_affected="33" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="132" subjects_affected="32" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Lymphopenia</sub_title>
                <counts group_id="E1" events="142" subjects_affected="37" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="64" subjects_affected="15" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Platelets</sub_title>
                <counts group_id="E1" events="115" subjects_affected="37" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW:: Transfusion: Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>COAGULATION:: Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>COAGULATION:: Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOVASCULAR (ARRHYTHMIA):: Prolonged QTc interval (QTc &gt; 0.48 seconds)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (ARRHYTHMIA):: Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (ARRHYTHMIA):: Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (ARRHYTHMIA):: Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR (GENERAL):: Hypotension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>AUDITORY/HEARING:: Auditory/Hearing-Other (Specify, pressure in right ear)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOCRINE:: Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>ENDOCRINE:: Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR/VISUAL:: Ocular/Visual-Other (Specify, transient vision lost)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL:: Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Gastrointestinal-Other (Specify, tongue discoloration)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Mouth dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL:: Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE:: Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS</description>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Rigors, chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS:: Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, ankle)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, Back)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, jaw pain/tightness)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, pain Lt axilla surgical site)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, pain: Back:sacral area)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, Rt shoulder pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, Rt great toe pain: ingrown toenail)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Pain-Other (Specify, Rt flank)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC:: Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>HEPATIC:: Bilirubin</sub_title>
                <counts group_id="E1" events="26" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>HEPATIC:: Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="31" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>HEPATIC:: SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="16" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>HEPATIC:: SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY:: Allergy-Other (Specify, sinus congestion)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA:: Catheter-related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>INFECTION/FEBRILE NEUTROPENIA:: Infection without neutropenia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Amylase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Bicarbonate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypercalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyperglycemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyperkalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypermagnesemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypernatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyperuricemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypocalcemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypoglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypokalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypomagnesemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hyponatremia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Hypophosphatemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Lipase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Specify, low zinc)</sub_title>
                <counts group_id="E1" events="58" subjects_affected="34" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Specify, low zinc serum)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Specify, serum zinc)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Specify, zinc)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Specify, zinc, low)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY:: Metabolic/Laboratory-Other (Specify, zinc-serum (low))</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL:: Musculoskeletal-Other (Specify, Akathisia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL:: Musculoskeletal-Other (Specify,muscle aches)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL:: Osteonecrosis (avascular necrosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Bone pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Chest pain (non-cardiac and non-pleuritic)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PAIN:: Tumor pain (onset or exacerbation of tumor pain due to treatment)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUROLOGY:: Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>NEUROLOGY:: Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PAIN:: Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE:: Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Creatinine</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Hemoglobinuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY:: Renal/Genitourinary-Other (Specify, hesitancy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>SEXUAL/REPRODUCTIVE FUNCTION:: Irregular menses (change from baseline)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN:: Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>PULMONARY:: Pulmonary-Other (Specify, upper respiratory infection)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dermatology/Skin-Other (Specify, eczematoid dermatitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dermatology/Skin-Other (Specify, rash; erythematous, eczematous)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Dermatology/Skin-Other (Specify, skin lesions)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN:: Rash/desquamation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Waldmann M.D.</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-496-6653</phone>
      <email>waldmann@nih.hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

